MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Search

AbCellera Biologics Inc

Fermé

SecteurSoins de santé

3.88 13.45

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.41

Max

3.9

Chiffres clés

By Trading Economics

Revenu

-22M

-57M

Ventes

-8.1M

9M

Marge bénéficiaire

-637.845

Employés

596

EBITDA

-1.4M

-40M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+94.46% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-569M

1B

Ouverture précédente

-9.57

Clôture précédente

3.88

Sentiment de l'Actualité

By Acuity

58%

42%

314 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

AbCellera Biologics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 janv. 2026, 18:06 UTC

Principaux Mouvements du Marché

LifeMD Shares Rise After Company Offers Novo Nordisk's Wegovy

5 janv. 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 janv. 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

5 janv. 2026, 23:51 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

5 janv. 2026, 23:42 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Lower on Likely Technical Correction -- Market Talk

5 janv. 2026, 21:52 UTC

Principaux Événements d'Actualité

Oil Stocks, Banks Push Dow to New Record -- WSJ

5 janv. 2026, 21:51 UTC

Principaux Événements d'Actualité

Palantir Stock Jumps. How It Benefited from the Venezuela Raid. -- Barrons.com

5 janv. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 janv. 2026, 21:38 UTC

Principaux Événements d'Actualité

Stock Market Today: Dow Jumps to Record After U.S. Captures Venezuela's Maduro -- WSJ

5 janv. 2026, 21:09 UTC

Acquisitions, Fusions, Rachats

SGH, Steel Dynamics Won't Need to Raise Equity to Fund Transaction

5 janv. 2026, 21:09 UTC

Acquisitions, Fusions, Rachats

SGH, Steel Dynamics to Fund Transaction With Cash, Available Debt Financing

5 janv. 2026, 21:08 UTC

Acquisitions, Fusions, Rachats

SGH Proposes Minimum One Board Position for BlueScope Directors to Maintain Continuity

5 janv. 2026, 21:06 UTC

Acquisitions, Fusions, Rachats

SGH, Steel Dynamics Offer Values BlueScope's Equity at A$13.2 Billion

5 janv. 2026, 21:06 UTC

Acquisitions, Fusions, Rachats

SGH Would Retain Remainder of BlueScope's Operations if Deal Completes

5 janv. 2026, 21:05 UTC

Acquisitions, Fusions, Rachats

SGH Would Sell BlueScope's North American Operations to Steel Dynamics if Deal Completes

5 janv. 2026, 21:05 UTC

Acquisitions, Fusions, Rachats

SGH, Steel Dynamics Offering A$30.00/Share in Cash to Acquire BlueScope

5 janv. 2026, 21:04 UTC

Acquisitions, Fusions, Rachats

SGH, Steel Dynamics Make Takeover Offer for BlueScope Steel

5 janv. 2026, 20:18 UTC

Market Talk

U.S. Natural Gas Extends Losses on Milder Weather Outlook -- Market Talk

5 janv. 2026, 20:08 UTC

Market Talk

Venezuela Needs Billions in Investment for Oil-Production Growth -- Market Talk

5 janv. 2026, 19:16 UTC

Market Talk
Principaux Événements d'Actualité

Alberta Says Canada Needs to Expedite Pipeline Projects Following Trump's Venezuela Move -- Market Talk

5 janv. 2026, 18:57 UTC

Market Talk
Principaux Événements d'Actualité

Quick Return of Venezuelan Oil Barrels A Possibility -- Market Talk

5 janv. 2026, 18:23 UTC

Market Talk

Moody's Should See Boost from Strong Debt Issuance Year -- Market Talk

5 janv. 2026, 18:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 janv. 2026, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

5 janv. 2026, 18:08 UTC

Market Talk
Principaux Événements d'Actualité

Canadian Heavy Oil Producers at Risk From a Revitalized Venezuela -- Market Talk

5 janv. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5 janv. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 janv. 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 janv. 2026, 17:08 UTC

Résultats

Strategy Records $17.44 Billion Unrealized Loss in Fourth Quarter -- WSJ

Comparaison

Variation de prix

AbCellera Biologics Inc prévision

Objectif de Prix

By TipRanks

94.46% hausse

Prévisions sur 12 Mois

Moyen 6.67 USD  94.46%

Haut 9 USD

Bas 4 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

4

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

1.99 / 2.635Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

314 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat